Pfizer Returns To Roivant As Development Partner For A Second Time

 
• By Jessica Merrill

Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.

partners
Pfizer and Roivant are teaming up on a new "vant" • Source: Shutterstock

More from Deals

More from Business